Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24NO4.CH3O4S |
| Molecular Weight | 429.485 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COS([O-])(=O)=O.[H][C@@]12O[C@]1([H])[C@H]3C[C@H](C[C@@H]2[N+]3(C)C)OC(=O)[C@H](CO)C4=CC=CC=C4
InChI
InChIKey=KHMGIQHRSVLFQG-RAFJPFSSSA-M
InChI=1S/C18H24NO4.CH4O4S/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;1-5-6(2,3)4/h3-7,12-17,20H,8-10H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1/t12-,13-,14-,15+,16-,17+;/m1./s1
Methscopolamine bromide is an anticholinergic agent used along with other medications to treat peptic ulcers by reducing stomach acid secretion. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications. Methscopolamine binds to M1-M5 isoforms of muscarinic receptors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL216 |
0.53 nM [Kd] | ||
Target ID: CHEMBL211 |
0.55 nM [Kd] | ||
Target ID: CHEMBL245 |
1.38 nM [Kd] | ||
Target ID: CHEMBL1821 |
0.44 nM [Kd] | ||
Target ID: CHEMBL2035 |
0.59 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PAMINE Approved UseMethscopolamine bromide is an anticholinergic agent which possesses most of the pharmacological actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia. Launch Date1953 |
|||
| Palliative | DALLERGY Approved UseThis product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product. |
|||
| Palliative | DALLERGY Approved UseThis product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. | 1997 Jul |
|
| Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. | 1998 Mar |
|
| A snake venom inhibitor to muscarinic acetylcholine receptor (mAChR): isolation and interaction with cloned human mAChR. | 2000 May 15 |
|
| Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. | 2002 Dec |
|
| Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors. | 2003 Jun 12 |
|
| Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. | 2005 Sep |
|
| Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. | 2006 Aug |
|
| Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist. | 2006 Jan |
|
| Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. | 2006 May |
|
| Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. | 2010 Oct |
Patents
Sample Use Guides
The average dosage of Methscopolamine Bromide Tablets USP is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.
Route of Administration:
Oral
In the standard assay, mAChR subtypes (20-30 fmol/tube) in particulate fractions of Sf9 cells were incubated with 4 to 4.2 nM [3H]NMS (methscopolamine) and different concentrations of muscarinic ligands in 20 mM K-phosphate buffer (pH 7). Bound [3H]NMS trapped on the filter was counted with a liquid scintillation counter.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB14159MIG
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY | |||
|
100000077608
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY | |||
|
R044N53C06
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201268
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY | |||
|
DTXSID50939371
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY | |||
|
SUB36127
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
ALTERNATIVE | |||
|
18067-13-5
Created by
admin on Sat Dec 16 04:41:28 GMT 2023 , Edited by admin on Sat Dec 16 04:41:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
